← All trials
NCT04348461
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 6, 2020
- Primary completion
- Sep 15, 2020
- Completion date
- Sep 30, 2020
- First posted
- Apr 16, 2020
- Last posted
- Apr 16, 2020
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Universidad Autonoma de MadridLead sponsor
- Clinica Universidad de NavarraCollaborator
- University of SalamancaCollaborator
- University AlicanteCollaborator
- Hospital General Universitario Gregorio MarañonCollaborator
- Hospital Clínica Universitario Virgen de la Arrixaca (SPAIN)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.